Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Cuidados contínuos em pacientes hospitalizados com transtorno por uso de opióides e complicações infecciosas decorrentes do uso de drogas (CHOICE-STAR)

5 de novembro de 2026 atualizado por: Elana Rosenthal

O cuidado contínuo em pacientes hospitalizados com transtorno por uso de opióides e complicações infecciosas do uso de drogas - NavSTAR, tratamento usual, clínica integrada de dependência/identificação para prevenir readmissão relacionada a infecções

This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.

Visão geral do estudo

Descrição detalhada

This is a phase III two arm randomized controlled trial to determine the impact and Integrated infectious diseases (ID) and Substance Use Disorder outpatient clinic (IC) compared to treatment as usual on infection related rehospitalization in individuals hospitalized with infections due to injecting opioids or Stimulants, in the 6 month time period after discharge. This study includes both cost effectiveness and implementation outcomes.

(1) IC will provide facilitated linkage to a clinic providing medical treatment aimed at treating substance use disorder (SUD), resolving the index infection, treating existing ID complications of OUD (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and medication for OUD (MOUD) treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and MOUD providers.

The study will recruit patients during hospitalization for an infection due to injecting opioids or stimulants at four hospital systems (five hospitals) and randomly assign approximately 304 inpatients in 1:1 ratio to IC vs TAU.

Participants will be followed for 12 months.

Tipo de estudo

Intervencional

Inscrição (Estimado)

304

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20052
        • Recrutamento
        • George Washington University
        • Subinvestigador:
          • Irene Kuo, MD
        • Contato:
        • Investigador principal:
          • Jill Catalanotti, MD
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Recrutamento
        • Emory University
        • Investigador principal:
          • Joseph Carpenter, MD
        • Contato:
        • Subinvestigador:
          • Alina Steck, MD
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • Recrutamento
        • University of Maryland Baltimore
        • Subinvestigador:
          • Edward Traver, MD
        • Investigador principal:
          • Elana Rosenthal, MD
        • Subinvestigador:
          • Sarah Kattakuzhy, MD
        • Contato:
    • West Virginia
      • Morgantown, West Virginia, Estados Unidos, 26506
        • Recrutamento
        • West Virginia University
        • Contato:
        • Investigador principal:
          • Rebecca Reece, MD
        • Subinvestigador:
          • Clinton Cooper, MD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Admitted to study hospital (defined as hospitalized with a primary team that is not Emergency Medicine)
  3. Injection opioid or stimulant use in past 90 days - per patient self-report
  4. Active suspected or confirmed qualifying infection (see list) at time of admission.

Qualifying infections:

  • Non-vertebral osteomyelitis
  • Vertebral osteomyelitis or discitis
  • Epidural, subdural, or extradural abscess
  • Intracranial or intraspinal abscess
  • Native joint septic arthritis
  • Prosthetic joint septic arthritis
  • Blood stream infection (bacterial or fungal)
  • Native valve Endocarditis
  • Prosthetic valve endocarditis
  • Cardiac Implantable electronic device infection
  • Infectious pseudoaneurysm and aneurysm
  • Infected vascular graft
  • Septic venous thrombosis
  • Skin and Soft tissue infection (cellulitis, skin abscess, necrotizing fasciitis)
  • Infected skin ulcer
  • Orthopedic hardware infection
  • Muscle abscess/myositis
  • Central nervous system infection (bacterial or fungal)
  • Bacterial or fungal ophthalmologic infection
  • Other abscess
  • Pulmonary septic emboli
  • Other acute bacterial or fungal infection deemed appropriate by site study team

Exclusion Criteria:

  • 1. Infection due to a cause other than injection drug use, per determination of a site PI.

    2. Inability to provide consent due to circumstance (e.g., sedated, intubated), language, or cognitive impairment.

    3. Unwilling to provide informed consent 4. Unable to receive potential interventions due to geography 5. On comfort measures or planned for discharge to hospice care 6. Incarcerated at the time of hospitalization 7. Other criteria at the discretion of the site investigator

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Treatment As Usual

Will receive treatment for infection and opioid or stimulant use disorder per the usual care at each hospital

Experimental: Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)

The Integrated ID/SUD Clinic will provide facilitated linkage to a clinic providing medical treatment aimed at treating SUD, resolving the sentinel infection, treating existing ID complications of OUD/stimulants (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and MOUD treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and SUD providers. The dual goals of the IC intervention are to 1) to facilitate accessibility to ID and OUD care and 2) to ensure care coordination between outpatient ID and SUD providers.

Integrated medication for opioid/stimulant use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Infection Rehospitalization
Prazo: 6 months after discharge for index hospitalization

New hospitalization due to infection following discharge for index hospitalization

6 months after discharge for index hospitalization

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Time to first infection related readmission
Prazo: 12 months after discharge for index hospitalization

Time to first infection related readmission

12 months after discharge for index hospitalization
Reason for infection related readmission
Prazo: 12 months after discharge for index hospitalization

Reason for infection related readmission (persistent index infection, new IDU associated infection, other infection)

12 months after discharge for index hospitalization
Hospital services utilization
Prazo: 12 months after discharge for index hospitalization

ED visits (Binary, count, time to first ED visit, cause) and Readmission, all cause (binary, count, time to first readmission, cause)

12 months after discharge for index hospitalization
Mortality
Prazo: 12 months after discharge for index hospitalization

Death (Binary, time to death, cause of death)

12 months after discharge for index hospitalization
Index infection
Prazo: 3 months after discharge for index hospitalization

Completion of antibiotics (binary, reason for incomplete antibiotics); Resolution of index infection (binary) Skilled Nursing Facility (SNF) Admitted to SNF (binary) Discharge type from SNF (planned, PDD, dead, transfer)

3 months after discharge for index hospitalization
Other Infections
Prazo: 12 months after discharge for index hospitalization

HCV Active HCV (binary) Clinical evaluation (binary) DAA prescribed (binary) DAA initiated (binary) SVR achieved (binary) HIV Diagnosis status (binary) HIV VL undetectable (binary) ART Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days) PrEP Eligible (CDC Criteria, binary, indication) Offered by healthcare provider (binary) Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days)

12 months after discharge for index hospitalization
Skin and soft tissue wounds
Prazo: 12 months after discharge for index hospitalization

Present (binary) Number (count) Per wound Size Location on body Duration (continuous)

12 months after discharge for index hospitalization
New infections not requiring hospitalization
Prazo: 12 months after discharge for index hospitalization
  • Present (binary)
  • Number (count)
12 months after discharge for index hospitalization
Outpatient linkage and retention
Prazo: 12 months after discharge for index hospitalization
  • Infectious Diseases Clinic (binary, time to linkage, count)
  • Medication for OUD Treatment (binary, time to linkage, count)
  • Non-medication based OUD Treatment (binary, time to linkage, count)
12 months after discharge for index hospitalization
Medication for Opioid Use (MOUD)
Prazo: 12 months after discharge for index hospitalization
  • On treatment (binary)
  • MOUD type
  • MOUD Dose
  • MOUD Dose adequacy
  • MOUD Source of medication
  • MOUD Location type
  • MOUD Co-location with other services
  • Reasons for no MOUD (descriptive)
12 months after discharge for index hospitalization
Medication for stimulant use (MStUD)
Prazo: 12 months after discharge for index hospitalization
  • On treatment (binary) MStUD type
  • MStUD Dose
  • MStUD Dose adequacy
  • MStUD Source of medication
  • MStUD Location type
  • MStUD Co-location with other services
  • Reasons for no MStUD (descriptive)
12 months after discharge for index hospitalization
Substance Use-Opioid
Prazo: 12 months after discharge for index hospitalization

Ongoing opioid (binary, mode)

  • Opioid use frequency
  • Mode of opioid use
  • Opioid craving
  • Other drug use (binary, mode)
  • Other drug use frequency
  • IDU (binary, frequency, mode (IM, IV, skin, other), location, syringe reuse, ssp engagement).
  • Severity (DAST)
  • Overdose (binary, count)
  • Tobacco use
  • UDS (binary - presence of opioids, )
12 months after discharge for index hospitalization
Substance Use - Stimulant
Prazo: 12 months after discharge for index hospitalization

Ongoing stimulant use (binary, mode)

  • Stimulant use frequency
  • Mode of stimulant use
  • Cocaine craving
  • Methamphetamine craving
  • Other drug use (binary, mode)
  • Other drug use frequency
  • IDU (binary, frequency, mode (IM, IV, skin, other), location, syringe reuse, ssp engagement).
  • Severity (DAST)
  • Overdose (binary, count)
  • Tobacco use
  • UDS (binary - presence of cocaine, amphetamines, other)
12 months after discharge for index hospitalization
Cost Effectiveness
Prazo: 12 months after discharge for index hospitalization

• ICER for quality adjusted life years (QALYs); opioid-free years (OfYs); and infection-free years (IfYs) gained

12 months after discharge for index hospitalization

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Elana Rosenthal, MD, University of Maryland, Baltimore

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de outubro de 2024

Conclusão Primária (Estimado)

30 de julho de 2027

Conclusão do estudo (Estimado)

30 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

8 de julho de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de julho de 2024

Primeira postagem (Real)

22 de julho de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

5 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever